New data on treatment outcomes using different sources of hematopoietic stem cells were presented at the American Society of Hematology conference in December 2023. It has been reported that transplantation of umbilical cord blood stem cells and haploidentical (half-matched) bone marrow allows to achieve better survival rates of patients than the use of haploidentical bone marrow alone.
Such results were obtained in the 3rd phase of a multicenter, randomized, open-label clinical trial in which 268 patients with acute myeloid leukemia were treated at 5 transplant centers in China (NCT03719534). In the group that received umbilical cord blood stem cells, the 3-year survival rate was 80.5% compared to 67.8% among patients who received only bone marrow cells.
This important message was announced in February 2024 by the authoritative international organization ParentsGuidetoCordBloodFoundation, whose activities are aimed at timely and objectively informing future parents about the possibilities of storage and clinical use of umbilical cord blood preparations.
As a reminder, cord blood has been used in medicine since 1988, and the number of successful applications has exceeded 60,000.
Source: https://parentsguidecordblood.org/en/news/haplo-cord-survival-better-haplo-transplants-alone
